PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations

被引：16

作者：

Layman, Rachel M. ^{[1
]}

Arun, Banu ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX USA

来源：

CANCER JOURNAL | 2021年 / 27卷 / 01期

关键词：

Basal-like; BRCA; BRCAness; breast cancer; homologous recombination deficiency; PARP inhibitor; poly(ADP-ribose) polymerase; triple-negative breast cancer; synthetic lethality;

D O I：

10.1097/PPO.0000000000000499

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose) polymerase (PARP) is involved in single-strand DNA break base excision repair. PARP inhibition causes synthetic lethality in breast cancers associated with germline BRCA1 and BRCA2 mutations and is routinely used in clinical practice for metastatic breast cancer. Breast cancers with homologous recombination deficiency or BRCAness, most commonly triple-negative breast cancers, may also benefit. Currently, PARP inhibitor use for triple-negative breast cancer with wild-type BRCA does not have definitive efficacy; however, this is an area of active research. Further clinical and translational data may identify additional patient populations that will benefit from PARP inhibitor therapy.

引用

页码：67 / 75

页数：9

共 52 条

[1] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer [J].

Andre, Fabrice ;

Ciruelos, Eva ;

Rubovszky, Gabor ;

Campone, Mario ;

Loibl, Sibylle ;

Rugo, Hope S. ;

Iwata, Hiroji ;

Conte, Pierfranco ;

Mayer, Ingrid A. ;

Kaufman, Bella ;

Yamashita, Toshinari ;

Lu, Yen-Shen ;

Inoue, Kenichi ;

Takahashi, Masato ;

Papai, Zsuzsanna ;

Longin, Anne-Sophie ;

Mills, David ;

Wilke, Celine ;

Hirawat, Samit ;

Juric, Dejan .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20) :1929-1940

[2] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

[3] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[4] Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer [J].

Dent, Rebecca A. ;

Lindeman, Geoffrey J. ;

Clemons, Mark ;

Wildiers, Hans ;

Chan, Arlene ;

McCarthy, Nicole J. ;

Singer, Christian F. ;

Lowe, Elizabeth S. ;

Watkins, Claire L. ;

Carmichael, James .

BREAST CANCER RESEARCH, 2013, 15 (05)

[5] Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors [J].

Dhawan, Mallika S. ;

Bartelink, Imke H. ;

Aggarwal, Rahul Raj ;

Leng, Jim ;

Zhang, Jenna Z. ;

Pawlowska, Nela ;

Barberio, Manuela Terranova ;

Grabowski, Jennifer ;

Gewitz, Andrew ;

Chien, Amy J. ;

Moasser, Mark ;

Kelley, Robin K. ;

Maktabi, Tayeba ;

Thomas, Scott ;

Munster, Pamela N. .

CLINICAL CANCER RESEARCH, 2017, 23 (21) :6400-6410

[6] Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Dieras, Veronique ;

Han, Hyo S. ;

Kaufman, Bella ;

Wildiers, Hans ;

Friedlander, Michael ;

Ayoub, Jean-Pierre ;

Puhalla, Shannon L. ;

Bondarenko, Igor ;

Campone, Mario ;

Jakobsen, Erik H. ;

Jalving, Mathilde ;

Oprean, Cristina ;

Palacova, Marketa ;

Park, Yeon Hee ;

Shparyk, Yaroslav ;

Yanez, Eduardo ;

Khandelwal, Nikhil ;

Kundu, Madan G. ;

Dudley, Matthew ;

Ratajczak, Christine K. ;

Maag, David ;

Arun, Banu K. .

LANCET ONCOLOGY, 2020, 21 (10) :1269-1282

[7] Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer (vol 114, pg 723, 2016) [J].

Drew, Yvette ;

Ledermann, Jonathan ;

Hall, Geoff ;

Rea, Daniel ;

Glasspool, Ros ;

Highley, Martin ;

Jayson, Gordon ;

Sludden, Julieann ;

Murray, James ;

Jamieson, David ;

Halford, Sarah ;

Acton, Gary ;

Backholer, Zoe ;

Mangano, Raffaella ;

Boddy, Alan ;

Curtin, Nicola ;

Plummer, Ruth .

BRITISH JOURNAL OF CANCER, 2016, 114 (12) :E21-E21

[8] Resistance to therapy caused by intragenic deletion in BRCA2 [J].

Edwards, Stacey L. ;

Brough, Rachel ;

Lord, Christopher J. ;

Natrajan, Rachael ;

Vatcheva, Radost ;

Levine, Douglas A. ;

Boyd, Jeff ;

Reis-Filho, Jorge S. ;

Ashworth, Alan .

NATURE, 2008, 451 (7182) :1111-U8

[9] Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial [J].

Ettl, J. ;

Quek, R. G. W. ;

Lee, K. -H. ;

Rugo, H. S. ;

Hurvitz, S. ;

Goncalves, A. ;

Fehrenbacher, L. ;

Yerushalmi, R. ;

Mina, L. A. ;

Martin, M. ;

Roche, H. ;

Im, Y. -H. ;

Markova, D. ;

Bhattacharyya, H. ;

Hannah, A. L. ;

Eiermann, W. ;

Blum, J. L. ;

Litton, J. K. .

ANNALS OF ONCOLOGY, 2018, 29 (09) :1939-1947

[10] Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].

Gelmon, Karen A. ;

Tischkowitz, Marc ;

Mackay, Helen ;

Swenerton, Kenneth ;

Robidoux, Andre ;

Tonkin, Katia ;

Hirte, Hal ;

Huntsman, David ;

Clemons, Mark ;

Gilks, Blake ;

Yerushalmi, Rinat ;

Macpherson, Euan ;

Carmichael, James ;

Oza, Amit .

LANCET ONCOLOGY, 2011, 12 (09) :852-861

← 1 2 3 4 5 6 →